Reading through the report in more detail the following was of particular interest. FTO levels appear to be x3 times the pre-radio therapy levels. this could easily result in benefits with all Radio-therapies + any cancer resistance caused by ferroptosis. As with Decitabine, the treatment itself upregulates FTO and thus aids in Zantrene wiping out the cancer via FTO inhibition. From the study a similar thing occurs with Radio-therapy and not just ferroptosis caused by NPC.
Whilst we await the Cardio protect results, I can only speculate on the MOA. But if this extends to other treatments beyond Dox and Carfilzomib that would be astonishing. Also cardio-renal indications can benefit greatly from cardio protection - if Zantrene's MOA works across the board.
The list goes on and on, is this what immuno-therapy research first started out like?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)